Small Lymphocytic Lymphoma Clinical Trials

41 studies are recruiting for small lymphocytic lymphoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

   This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: * obinutuzumab * venetoclax * acalabrutinib

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Massachusetts General Hospital Cancer Center, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT04560322 on ClinicalTrials.gov

2. Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

   This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV20 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV20 and PPSV23 are both vaccines that protect against bacteria that cause pneumococcal disease. Giving these va…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah

   Run by

   University of Utah

   See if you can join NCT05183854 on ClinicalTrials.gov

3. Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

   This phase II trial tests whether acalabrutinib, venetoclax, and durvalumab work in treating patients with Richter transformation from chronic lymphocytic leukemia or small lymphocytic lymphoma. Richter transformation is a rare condition in which chronic lymphocytic leukemia or small lymphocytic ly…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Mayo Clinic in Rochester, Rochester, Minnesota

   Locations

   3 in total

   Run by

   Mayo Clinic

   See if you can join NCT05388006 on ClinicalTrials.gov

4. Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

   This phase II trial tests the effect of venetoclax and obinutuzumab followed by epcoritamab in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that have not previously received treatment. Venetoclax is in a class of medications called B-cell lymphoma-2 …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   7 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT07218510 on ClinicalTrials.gov

5. Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

   This phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic lymphocytic leukemia . Acalabrutinib is also an inhibitor that works in the body to block the activation of certain cells that lead to the g…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Ohio State University Comprehensive Cancer Center

   See if you can join NCT05336812 on ClinicalTrials.gov

6. Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

   This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with covalent bruton tyrosine kinase inhibitors (BTKi). Pirtobrutinib is in a …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Kerry Rogers

   See if you can join NCT06466122 on ClinicalTrials.gov

7. Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

   This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   New England Cancer Specialists, Scarborough, Maine

   Locations

   4 in total

   Run by

   Inhye Ahn

   See if you can join NCT06333262 on ClinicalTrials.gov

8. Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

   This phase II trial compares the effect of initial vaccination (PCV20 followed by PSV23) with yearly vaccinations of PSV23 to the standard 5 year vaccination in patients with chronic lymphocytic leukemia. At present chronic lymphocytic leukemia patients are poorly protected by anti-pneumococcal vac…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Run by

   Seema Bhat

   See if you can join NCT05417165 on ClinicalTrials.gov

9. Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

   This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Cincinnati, Cincinnati, Ohio

   Run by

   Zulfa Omer

   See if you can join NCT07014917 on ClinicalTrials.gov

10. Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

    This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Cincinnati, Cincinnati, Ohio

    Run by

    Zulfa Omer

    See if you can join NCT07108998 on ClinicalTrials.gov

11. Mosunetuzumab for CLL MRD Clearance

    The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic lymphocytic leukemia) or small lymphocytic lymphoma (SLL). The names of th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Brigham & Women's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Inhye Ahn

    See if you can join NCT07052695 on ClinicalTrials.gov

12. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

    This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC Irvine Health, Orange, California

    Locations

    13 in total

    Run by

    Carna Biosciences, Inc.

    See if you can join NCT05602363 on ClinicalTrials.gov

13. Two Step Haplo With Radiation Conditioning

    This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however th…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT05031897 on ClinicalTrials.gov

14. A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

    People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is …

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    San Francisco VA Medical Center, San Francisco, CA, San Francisco, California

    Locations

    4 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT06520098 on ClinicalTrials.gov

15. Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

    This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    OHSU Knight Cancer Institute, Portland, Oregon

    Run by

    OHSU Knight Cancer Institute

    See if you can join NCT06784167 on ClinicalTrials.gov

16. LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

    Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Cincinnati Medical Center, Cincinnati, Ohio

    Run by

    Zulfa Omer

    See if you can join NCT06978088 on ClinicalTrials.gov